Role of DAT‐SPECT in the diagnostic work up of Parkinsonism
暂无分享,去创建一个
E. Tolosa | W. Oertel | W. Poewe | F. Valldeoriola | K. Marek | A. Lees | C. Scherfler | A. Antonini | D. Grosset | J. Schwarz
[1] H. Berendse,et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease , 2004, Annals of neurology.
[2] Klaus Seppi,et al. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. , 2006, Archives of neurology.
[3] S. Gacinovic,et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.
[4] M. Critchley,et al. Arteriosclerotic Parkinsonism , 1930, Edinburgh medical journal.
[5] I. Podreka,et al. β-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo , 2005, Journal of Neural Transmission / General Section JNT.
[6] David J Brooks,et al. Imaging end points for monitoring neuroprotection in Parkinson's disease , 2003, Annals of neurology.
[7] Thomas Hummel,et al. Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT , 2004, Movement disorders : official journal of the Movement Disorder Society.
[8] P. Thompson,et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system , 1992, Neurology.
[9] Eileen O. Smith,et al. Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease , 1995, Annals of neurology.
[10] M. Lakie,et al. A study of the early signs of drug induced parkinsonism. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[11] K. Jellinger. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies , 2004, Neurology.
[12] A. Lang,et al. Psychogenic movement disorders , 2009, Current opinion in neurology.
[13] J S Rakshi,et al. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.
[14] G. Uhl,et al. Phosphatidylinositol 3-Kinase, Protein Kinase C, and MEK1/2 Kinase Regulation of Dopamine Transporters (DAT) Require N-terminal DAT Phosphoacceptor Sites* , 2003, Journal of Biological Chemistry.
[15] D. Mash,et al. Dopaminergic innervation of the human striatum in Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[16] J. Seibyl,et al. Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT , 1999, Movement disorders : official journal of the Movement Disorder Society.
[17] I. McKeith,et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease , 2004, Neurology.
[18] T. Yen,et al. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] O. Pogarell,et al. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years , 2001, Nuclear medicine communications.
[20] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[21] L. Deecke,et al. [123I]β‐CIT spect in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration , 2000, Movement disorders : official journal of the Movement Disorder Society.
[22] Willibald Gerschlager,et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study , 2002, Movement disorders : official journal of the Movement Disorder Society.
[23] H. Berendse,et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell , 2001, Annals of neurology.
[24] D. Brooks,et al. Long duration asymmetrical postural tremor is likely to predict development of Parkinson’s disease and not essential tremor: clinical follow up study of 13 cases , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[25] W. Gibb,et al. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[26] M. Onofrj,et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.
[27] K. Jellinger,et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. , 1996, Neurology.
[28] Robert B. Innis,et al. [123I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy , 2001 .
[29] A. Kessels,et al. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes , 2007, BMC neurology.
[30] Walter Paulus,et al. Dyskinesias due to intravenous apomorphine abuse in a patient without basal ganglia disorder , 2005, Movement disorders : official journal of the Movement Disorder Society.
[31] S Fahn,et al. Tolcapone , 1998, Neurology.
[32] J. Seibyl,et al. [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.
[33] J. Penney,et al. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson’s disease brains , 1998, Journal of neurology, neurosurgery, and psychiatry.
[34] Claude Nahmias,et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.
[35] Thomas Behr,et al. Dopamine transporter imaging and SPECT in diagnostic work‐up of Parkinson's disease: A decision‐analytic approach , 2003, Movement disorders : official journal of the Movement Disorder Society.
[36] John Seibyl,et al. Dopamine agonists and Parkinson's disease progression: What can we learn from neuroimaging studies , 2003, Annals of neurology.
[37] P B Hoffer,et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] E. Tolosa,et al. Transient arrest of psychogenic tremor induced by contralateral ballistic movements , 2004, Neuroscience Letters.
[39] G. Wooten. Agonists vs levodopa in PD: The thrilla of whitha , 2003 .
[40] Lee-Tzuu Chang,et al. A Method for Attenuation Correction in Radionuclide Computed Tomography , 1978, IEEE Transactions on Nuclear Science.
[41] E. Tolosa,et al. Impact of dopamine transporter SPECT using 123I‐Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes , 2004, Movement disorders : official journal of the Movement Disorder Society.
[42] Jan Booij,et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.
[43] J. C. Stoof,et al. Drug-naive patients with Parkinson’s disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]β-CIT SPECT , 1997, Journal of Neurology.
[44] W. Koch,et al. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] Kazuto Yoshida,et al. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease , 2005, Clinical Neurology and Neurosurgery.
[46] P. Hobson,et al. Accuracy of diagnosis in patients with presumed Parkinson's disease. , 1999, Age and ageing.
[47] E. Tolosa,et al. 123I‐Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism , 2006, Movement disorders : official journal of the Movement Disorder Society.
[48] J S Fowler,et al. Mechanism of action of methylphenidate: Insights from PET imaging studies , 2002, Journal of attention disorders.
[49] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[50] P. Tienari,et al. How useful is [123I]β-CIT SPECT in clinical practice? , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[51] S. Asenbaum,et al. [123I]β-CIT and SPECT in essential tremor and Parkinson's disease , 1998, Journal of Neural Transmission.
[52] G. Wenning,et al. Multiple system atrophy: An update , 2003, Movement disorders : official journal of the Movement Disorder Society.
[53] A. Rajput,et al. Anomalies of asymmetry of clinical signs in parkinsonism , 2004, Movement disorders : official journal of the Movement Disorder Society.
[54] L. Forno. Reaction of the substantia nigra to massive basal ganglia infarction , 2004, Acta Neuropathologica.
[55] J. Seibyl,et al. Hemi‐parkinsonism due to a midbrain arteriovenous malformation: dopamine transporter imaging , 2001, Movement disorders : official journal of the Movement Disorder Society.
[56] B. Bloem,et al. [123I]β‐CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[57] H. Panitch,et al. Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange. , 2002, Neurology.
[58] J. Jankovic. Essential tremor course and disability: A clinicopathologic study of 20 cases , 2004, Neurology.
[59] Yoav Ben-Shlomo,et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.
[60] R. Djaldetti,et al. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[61] J. Javitch,et al. N-Terminal Phosphorylation of the Dopamine Transporter Is Required for Amphetamine-Induced Efflux , 2004, PLoS biology.
[62] P. Morrish. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? , 2003, Movement disorders : official journal of the Movement Disorder Society.
[63] I. Podreka,et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT , 1997 .
[64] J. Javitch,et al. Akt Is Essential for Insulin Modulation of Amphetamine-Induced Human Dopamine Transporter Cell-Surface Redistribution , 2005, Molecular Pharmacology.
[65] J. Jolles,et al. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). , 2003, Neuropediatrics.
[66] W. Oertel,et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. , 2004, Brain : a journal of neurology.
[67] A. Cagnin,et al. Thiethylperazine‐induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade , 2004, European journal of neurology.
[68] D Oakes,et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease , 2003, Experimental Neurology.
[69] L. Thal,et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? , 2006, Brain : a journal of neurology.
[70] J. Sundsfjord,et al. 123I-β-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia , 2004, Psychopharmacology.
[71] Stephen A. Williams,et al. Changes in Human In vivo Serotonin and Dopamine Transporter Availabilities during Chronic Antidepressant Administration , 2003, Neuropsychopharmacology.
[72] I. McKeith,et al. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using 123I-FP-CIT SPECT , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[73] C. Katona,et al. In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies , 1999, The Lancet.
[74] S. Asenbaum,et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. , 1997, Journal of neural transmission. Supplementum.
[75] E. Montgomery,et al. Slowing Parkinson’s disease progression: Recent dopamine agonist trials , 2004, Neurology.
[76] Klaus Seppi,et al. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. , 2005, Brain : a journal of neurology.
[77] Andrew J. Lees,et al. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease , 2001, Neurology.
[78] L. Deecke,et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[79] Christian Kolbitsch,et al. Evaluation of Striatal Dopamine Transporter Function in Rats by in Vivo β-[123I]CIT Pinhole SPECT , 2002, NeuroImage.
[80] D. Grosset,et al. The role of radiotracer imaging in Parkinson disease , 2005, Neurology.
[81] B Bioulac,et al. Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2001, The Journal of Neuroscience.
[82] J. Jankovic,et al. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. , 2000, Archives of neurology.
[83] J B Habraken,et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[84] M. Canesi,et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy , 2003, Neurological Sciences.
[85] David Oakes,et al. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. , 2004, Archives of neurology.
[86] J. Unterrainer,et al. Measuring the progression of idiopathic Parkinson's disease with [123I] β-CIT SPECT , 2000, Journal of Neural Transmission.
[87] Werner H. Mess,et al. Diagnostic Value of 123I-Ioflupane and 123I-Iodobenzamide SPECT Scans in 248 Patients with Parkinsonian Syndromes , 2008, European Neurology.
[88] Andrew J Lees,et al. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis , 2004, Movement disorders : official journal of the Movement Disorder Society.
[89] S. Fahn,et al. Phenomenology and psychopathology related to psychogenic movement disorders. , 1995, Advances in neurology.
[90] H. Melikian,et al. Membrane Trafficking Regulates the Activity of the Human Dopamine Transporter , 1999, The Journal of Neuroscience.
[91] S. Asenbaum,et al. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. , 1998, Journal of neural transmission.
[92] J. P. Seibyl,et al. [sup 123 I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease , 1996, Neurology.
[93] C. Katona,et al. Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon mission tomography , 1997, European Journal of Nuclear Medicine.
[94] D. Linszen,et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT , 2001, Schizophrenia Research.
[95] Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.
[96] I. McKeith,et al. Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies , 2005, International journal of geriatric psychiatry.
[97] S. Gilman,et al. Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.
[98] A. Lees,et al. [123I]-FP-CIT-SPECT in the early diagnosis of PD presenting as exercise-induced dystonia , 2002, Neurology.
[99] R. Felix,et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients , 2005, Journal of Neural Transmission.
[100] E. Tolosa,et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD , 2005, Neurology.
[101] D. Costa,et al. Dementia with Lewy bodies versus Alzheimer's disease: Role of dopamine transporter imaging , 2003, Movement disorders : official journal of the Movement Disorder Society.
[102] P. Acton,et al. Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT , 2004, IEEE Symposium Conference Record Nuclear Science 2004..
[103] R. Wityk,et al. Cardiac surgery and magnetic resonance imaging of the brain. , 2002, Archives of neurology.
[104] A. Lees,et al. Confirming Parkinson's disease with 123 I-FP-CIT SPECT , 1999 .
[105] L. Thal,et al. The Lewy body variant of Alzheimer's disease , 1990, Neurology.
[106] M Laruelle,et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[107] D J Wyper,et al. Correlation of Parkinson's disease severity and duration with 123I‐FP‐CIT SPECT striatal uptake , 2000, Movement disorders : official journal of the Movement Disorder Society.
[108] J. Gorman,et al. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications , 2003, Psychopharmacology.
[109] Perry E Radau,et al. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[110] D. Mash,et al. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons , 1994, Annals of neurology.
[111] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.
[112] H. Bracha,et al. Asymmetry of neuroleptic-induced rigidity: Development of quantitative methods and clinical correlates , 1989, Psychiatry Research.